David Wong, is an Honours graduate from the University of Toronto’s Medical Doctorate program who specializes in Vitreous and Retina surgery after completing a residency in ophthalmology at U of T and a fellowship with Dr. Michael Shea in Toronto followed by a second fellowship with Dr. Stanley Chang in Columbia, New York. Dr. Wong is a fellow of the Royal College of Physicians and Surgeons of Canada and is certified by the American Board of Ophthalmology. He is also a member of the Canadian Ophthalmology Society, the American Academy of Ophthalmology, the American Society of Retina Specialists and the Association for Research in Vision and Ophthalmology. His present Academic appointment includes Associate Professor, University of Toronto and is on staff at St. Michael's Hospital, Oakville Trafalgar Hospital and Trillium Hospital. He is Ophthalmologist-in-Chief at St. Michael’s Hospital and sits on numerous hospital and University committees. Dr. Wong is on the board of directors for the 20/20 Ophthalmic Biomaterials Network, and consultant to several companies in industry as well as on the steering committee of the Vision Acadamy. Numerous awards have been given to him locally and internationally including the American Society of Vitreoretinal Surgeons (ASRS) Senior Award. He is the past director of the fellowship programs in the Department of Ophthalmology and Vision Sciences at the University of Toronto and has founded the national fellowship committee in the Canadian Ophthalmology Society. Locally he started the GTA Retina subspecialty group rounds in 1998 which has been running ever since. He has been a frequent invited speaker in North and South America, Asia and Europe and has authored numerous scientific papers and book chapters in various areas of vitreoretinal diseases including trauma, complex surgeries, new surgical techniques, AMD, retinal vein occlusions and diabetes. In addition he commits time to do missionary work including being one of the founders of the Philippines Urban Angels Mission group. His recent interests include better diabetic retinopathy surveillance that may catch the disease in the earlier stages and developing new ophthalmic biomaterials.

Financial disclosure: I have/had an affiliation (financial or otherwise) with a commercial organization: 

1. Alcon
2. Allergan
3. Bayer
4. Genentech
5. Novartis
6. Valeant